title: Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter.
abstract: BACKGROUND
  Despite the high success rate of radiofrequency (RF) ablation, pharmacologic therapy is still considered the standard initial therapeutic approach for atrial flutter.
  
  
  OBJECTIVE
  We prospectively compared the outcome at follow-up of patients with atrial flutter randomly assigned to drug therapy or RF ablation.
  
  
  METHODS
  Patients with at least two episodes of symptomatic atrial flutter in the last four months were randomized to regimens of either antiarrhythmic drug therapy or first-line RF ablation. After institution of therapy, end points included recurrence of atrial flutter, rehospitalization and quality of life.
  
  
  RESULTS
  A total of 61 patients entered the study, 30 of whom were randomized to drug therapy and 31 to RF ablation. After a mean follow-up of 21 +/- 11 months, 11 of 30 (36%) patients receiving drugs were in sinus rhythm, versus 25 of 31 (80%) patients who underwent RF ablation (p < 0.01). Of the patients receiving drugs, 63% required one or more rehospitalizations, whereas post-RF ablation, only 22% of patients were rehospitalized (p < 0.01). Following RF ablation, 29% of patients developed atrial fibrillation which was seen in 53% of patients receiving medications (p < 0.05). Sense of well being (pre-RF 2.0 +/- 0.3 vs. post-RF 3.8 +/- 0.5, p < 0.01) and function in daily life (pre-RF 2.3 +/- 0.4 vs. post-RF 3.6 +/- 0.6, p < 0.01) improved after ablation, but did not change significantly in patients treated with drugs.
  
  
  CONCLUSIONS
  In a selected group of patients with atrial flutter, RF ablation could be considered a first-line therapy due to the better success rate and impact on quality of life, the lower occurrence of atrial fibrillation and the lower need for rehospitalization at follow-up.
authors.affiliation: Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195, USA. natalea@ccf.org
authors.forename: A
authors.initials: A
authors.lastname: Natale
authors.forename: K H
authors.initials: KH
authors.lastname: Newby
authors.forename: E
authors.initials: E
authors.lastname: Pisanó
authors.forename: F
authors.initials: F
authors.lastname: Leonelli
authors.forename: R
authors.initials: R
authors.lastname: Fanelli
authors.forename: D
authors.initials: D
authors.lastname: Potenza
authors.forename: S
authors.initials: S
authors.lastname: Beheiry
authors.forename: G
authors.initials: G
authors.lastname: Tomassoni
mesh_terms: D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001282:Atrial Flutter / Q000188:drug therapy* / Q000601:surgery*; D017115:Catheter Ablation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011446:Prospective Studies; D011788:Quality of Life
chemical_list: D000889:Anti-Arrhythmia Agents